NeOnc Technologies appoints Josh Neman as Chief Clinical Officer

NEONC TECHNOLOGIES HOLDINGS, INC.

Josh Neman appointed Chief Clinical Officer effective June 5, 2025; base salary $165,000/year.
Granted 200,000 RSUs: 1/3 vest Dec 30, 2025; 1/3 in 29 monthly installments; 1/3 performance-based.
Neman will continue his role as Associate Professor at USC Keck School of Medicine.
Neman also serves as CEO of Synaptical Inc. and CNSMENDER Consulting.
Employment term is 12 months with automatic annual renewal; at-will employment.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Josh Neman

Chief Clinical Officer

NTHI · NEONC TECHNOLOGIES HOLDINGS, INC.

Effective: 2025-06-05
Filed: June 6, 2025, 7:59 PM ET

The Board of Directors (the “Board”) of the Company appointed Josh Neman as the Company’s Chief Clinical Officer, effective June 5, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Josh Neman was appointed as Chief Clinical Officer at NEONC TECHNOLOGIES HOLDINGS, INC..

Action: appointed
Role: Chief Clinical Officer

Exact text from the filing

The Board of Directors (the “Board”) of the Company appointed Josh Neman as the Company’s Chief Clinical Officer, effective June 5, 2025.

View on SEC.gov

NEONC TECHNOLOGIES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001829126-25-004324

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.